Publicaties 2008

Biemond BJ, Giordano PC.Hemoglobinopathieën: abnormale hemoglobines en thalassemieën - hoofdstuk 6.  In: Löwenberg B, Ossenkoppele GJ, editors. Handboek Hematologie. Utrecht: De Tijdstroom; 2008. p. 65-80.

Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M, Roos D, de Haas M, Koene HR, Kuijpers TW. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. BLOOD 2008;111(3):1029-1038.     [ PubMed ]

Cerveira N, Santos J, Pinheiro M, Snijder S, van der Lelie H, Mellink CHM, Teixeira MR. A novel MLL-SEPT2 fusion variant in therapy-related myelodysplastic syndrome. CANCER GENET CYTOGEN 2008;185(1):62-64.  

Chitty LS, van der Schoot CE, Hahn S, Avent ND. SAFE--the Special Non-invasive Advances in Fetal and Neonatal Evaluation Network: aims and achievements. PRENATAL DIAG 2008;28(2):83-88.     [ PubMed ]

Choi G, van den Borne MPJ, Visser CE, Kersten MJ, Kater AP. Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature. ANN HEMATOL 2008;87(9):771-772.     [ PubMed ]

Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MHJ, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. BLOOD 2008;111(3):1094-1100.     [ PubMed ]

Deenik W, van der Holt B, Verhoef GEG, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AVMB, Janssen JJWM, Sonneveld P, Kooy MVM, Wittebol S, Willemze R, Wijermans PW, Westveer PHM, Beverloo HB, Valk P, Loewenberg B, Ossenkoppele GJ, Cornelissen JJ. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. BLOOD 2008;111(5):2581-2588.  

de Fost M. Gaucher disease type 1; associated morbidities and long term efficcacy of enzyme replacement therapy. s.l.: s.n.; 2008. (196pp.) (PhD thesis. Supervisor(s):  Aerts JMFG, van Oers MHJ; co-supervisor(s):  Hollak CEM) [ UvA Dissertations Online ]

de Fost M, Out TA, de Wilde FA, Tjin EPM, Pals ST, van Oers MHJ, Boot RG, Aerts JFMG, Maas M, vom Dahl S, Hollak CEM. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. ANN HEMATOL 2008;87(6):439-449.     [ PubMed ]

de Gorter DJJ, Reijmers RM, Beuling EA, Naber HPH, Kuil A, Kersten MJ, Pals ST, Spaargaren M. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. BLOOD 2008;111(7):3364-3372.     [ PubMed ]

Dohmen SE. The human immune response to Rh antigens. s.l.: s.n.; 2008. (158pp.) (ISBN 9789090228549) (PhD thesis. Supervisor(s):  van der Schoot CE) [ UvA Dissertations Online ]

Dohmen SE, Muit J, Ligthart PC, Verhagen OJHM, van der Schoot CE. Anti-e found in a case of hemolytic disease of the fetus and newborn make use of the IGHV3 superspecies genes. TRANSFUSION 2008;48(1):194-195.     [ PubMed ]

Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH, de Jong D, Eldering E, van Oers MHJ, Mellink CHM, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J MOL DIAGN 2008;10(5):442-451.     [ PubMed ]

Hagenbeek A. Monoclonal antibodies (novel): Humax-CD20, Ofatumumab. HEMATOL MEETINGS REPORTS 2008;2:79-80.  

Hagenbeek A. Monoclonal antibodies (update): CD20, Rituximab. HEMATOL MEETINGS REPORTS 2008;2:50-51.  

Hagenbeek A. Response: Multiple administrations of the fully human monoclonal antibody Ofatumumab. BLOOD 2008;112(6):2585.     [ PubMed ]

Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. BLOOD 2008;111(12):5486-5495.     [ PubMed ]

Hagenbeek A, Kluin PM, Schouten HCM. Non-Hodgkin lymfomen [hfdstk 29].  In: Löwenberg B, Ossenkoppele GJ, editors. Handboek Hematologie. Utrecht: De Tijdstroom; 2008. p. 405-442.

Hallaert DYH. 'From the cradle to the grave' : novel therapeutic approaches to attack the microenvironment in chronic lymphocytic leukemia. s.l.: s.n.; 2008. (171pp.) (ISBN 9789090235479) (PhD thesis. Supervisor(s):  van Oers MH; co-supervisor(s):  Eldering E) [ UvA Dissertations Online ]

Hallaert DYH, Jaspers A, van Noesel CJ, van Oers MHJ, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. BLOOD 2008;112(13):5141-5149.     [ PubMed ]

Hirsch A, Nijveldt R, van der Vleuten PA, Tio RA, van der Giessen WJ, Marques KMJ, Doevendans PA, Waltenberger J, ten Berg JM, Aengevaeren WRM, Biemond BJ, Tijssen JGP, van Rossum AC, Piek JJ, Zijlstra F. Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: Pilot study of the multicenter HEBE trial. CATHETER CARDIO INTE 2008;71(3):273-281.     [ PubMed ]

Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. HAEMATOL-HEMATOL J 2008;93(11):1702-1711.     [ PubMed ]

Kater AP , van Oers MHJ. De plaats van alemtuzumab bij de behandeling van chronische lymfatische leukemie. NED TIJDSCHR HEMATOL 2008;5(6):236-244.  

Koelewijn JM, de Haas M, Vrijkotte TGM, Bonsel GJ, van der Schoot CE. One single dose of 200 mu g of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. TRANSFUSION 2008;48(8):1721-1729.     [ PubMed ]

Koelewijn JM, Vrijkotte TGM, van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. TRANSFUSION 2008;48(5):941-952.     [ PubMed ]

Landburg PP, Teerlink T, van Beers EJ, Muskiet FAJ, Kappers-Klunne MC, van Esser JWJ, Mac Gillavry MR, Biemond BJ, Brandjes DPM, Duits AJ, Schnog JJ. Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension. HAEMATOL-HEMATOL J 2008;93(9):1410-1412.  

Legler TJ, Heermann KH, Liu Z, Soussan AA, van der Schoot CE. Fetal DNA: strategies for optimal recovery. METHODS MOL BIOL 2008;444:209-218.     [ PubMed ]

Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GMJ, Croockewit S, Zweegman S, Breitkreuz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MHJ, Schaafsma R, Naumann R, Sinnige H, Blau I, Verhoef G, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. HAEMATOL-HEMATOL J 2008;93(1):124-127.     [ PubMed ]

Lokhorst HM, Zweegman S, Kersten MJ , Raymakers RAP, Vellenga E, Wittebol S, Sonneveld P. Richtlijnen behandeling multipel myeloom anno 2008. NED TIJDSCHR HEMATOL 2008;5(4):150.  

Macklis R, Hagenbeek A. Frontline postchemotherapy consolidation with 90Y-Zevalin RIT: Finally an ideal role for RIT in lymphoma management?. AM J HEMATOL 2008;5:190-192.  

Mank A, Molenaar S. An interactive CD-ROM to inform patients about Stem Cell Transplantation. PATIENT EDUC COUNS 2008;73(1):121-126.     [ PubMed ]

Mank AP, Davies M. Examining low bacterial dietary practice: A survey on low bacterial food. EUR J ONCOL NURS 2008;12(4):342-348.     [ PubMed ]

Minnema MC, van de Donk NWCJ, Zweegman S, Hegenbart U, Schonland S, Raymakers R, Zijlmans JMJM, Kersten MJ , Bos GMJ, Lokhorst HM. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. BONE MARROW TRANSPL 2008;41(9):779-784.  

Morschhauser F, Radford J, van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Diaz MG, Petrini M, Sebban C, Zinzani PL, van Oers MHJ, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. J CLIN ONCOL 2008;26(32):5156-5164.     [ PubMed ]

Mous R. Studies on the immune system in CLL.. s.l.: s.n.; 2008. (165pp.) (ISBN 9789088910623) (PhD thesis. Supervisor(s):  van Oers MHJ, van Lier RAW; co-supervisor(s):  Eldering EF) [ UvA Dissertations Online ]

Mous R, Savage P, Eldering E, Teeling P, van Oers MH, van Lier RA. Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands. LEUKEMIA LYMPHOMA 2008;49(8):1592-1602.     [ PubMed ]

Piriou E, van Dort K, Otto S, van Oers MHJ, van Baarle D. Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection. CLIN INFECT DIS 2008;46(2):313-316.     [ PubMed ]

Potting CMJ, Mank A, Blijlevens NMA, Donnelly JP, van Achterberg T. Providing oral care in haematological oncology patients: nurses' knowledge and skills. EUR J ONCOL NURS 2008;12(4):291-298.     [ PubMed ]

Snijder S, Mellink CHM, van der Lelie H. Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. CANCER GENET CYTOGEN 2008;180(2):149-152.     [ PubMed ]

Sonke GS, Ludwig I, van Oosten H, Baars JW, Meijer E, Kater AP, de Jong D. Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. CLIN INFECT DIS 2008;47(1):105-108.     [ PubMed ]

Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM. PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma. J CLIN ONCOL 2008;26(33):5443-5449.     [ PubMed ]

Tijssen MR. From stem cell to platelet. s.l.: s.n.; 2008. (151pp.) (ISBN 9789090226293) (PhD thesis. Supervisor(s):  van der Schoot CE, Roos D; co-supervisor(s):  Voermans C, Zwaginga JJ) [ UvA Dissertations Online ]

Tijssen MR, di Summa F, van den Oudenrijn S, Zwaginga JJ, van der Schoot CE, Voermans C, de Haas M. Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia. BRIT J HAEMATOL 2008;141(6):808-813.     [ PubMed ]

Tijssen MR, van Hennik PB, di Summa F, Zwaginga JJ, van der Schoot CE, Voermans C. Transplantation of human peripheral blood CD34-positive cells in combination with ex vivo generated megakaryocytes results in fast platelet formation in NOD/SCID mice. LEUKEMIA 2008;22(1):203-208.     [ PubMed ]

Tijssen MR, Woelders H, de Vries-van Rossen A, van der Schoot CE, Voermans C, Lagerberg JWM. Improved postthaw viability and in vitro functionality of peripheral blood hematopoietic progenitor cells after cryopreservation with a theoretically optimized freezing curve. TRANSFUSION 2008;48(5):893-901.     [ PubMed ]

Tonino SH, Spijker R, Luijks DMP, van Oers MHJ, Kater AP. No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. BLOOD 2008;112(3):840-843.     [ PubMed ]

van Beem RT. Supporting cells in neovascularization. s.l.: s.n.; 2008. (170pp.) (ISBN 9789071382420) (PhD thesis. Supervisor(s):  van der Schoot CE; co-supervisor(s):  Zwaginga JJ) [ UvA Dissertations Online ]

van Beem RT, Hirsch A, Lommerse IM, Zwaginga JJ, Noort WA, Biemond BJ, Piek JJ, van der Schoot CE, Voermans C. Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction. EUROINTERVENTION 2008;4(1):133-138.     [ PubMed ]

van Beem RT, Noort WA, Voermans C, Kleijer M, ten Brinke A, van Ham SM, van der Schoot CE, Zwaginga JJ. The presence of activated CD4(+) T cells is essential for the formation of colony-forming unit-endothelial cells by CD14(+) cells. J IMMUNOL 2008;180(7):5141-5148.     [ PubMed ]

van Beers EJ. Sickle cell disease, pathophysiology and clinical complications.. s.l.: s.n.; 2008. (187pp.) (ISBN 9789090233994) (PhD thesis. Supervisor(s):  van Oers MHJ; co-supervisor(s):  Biemond BJ, Schnog JB) [ UvA Dissertations Online ]

van Beers EJ, Goedhart PT, Unger M, Biemond BJ, Ince C. Normal sublingual microcirculation during painful crisis in sickle cell disease. MICROVASC RES 2008;76(1):57-60.     [ PubMed ]

van Beers EJ, Nieuwdrop M, Duits AJ, Evers LM, Schnog JJB, Biemond BJ. Sickle cell patients are characterized by a reduced glycocalyx volume. HAEMATOL-HEMATOL J 2008;93(2):307-308.     [ PubMed ]

van Beers EJ, Nur E, Schaefer-Prokop CM, Mac Gillavry MR, van Esser JWJ, Brandjes DPM, Kappers-Klunne MC, Duits AJ, Muskiet FAJ, Schnog JJB, Biemond BJ. Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. AM J HEMATOL 2008;83(11):850-854.     [ PubMed ]

van Beers EJ, Spronk HMH, ten Cate H, Duits AJ, Brandjes DPM, van Esser JWJ, Biemond BJ, Schnog JB. No association of the hypercoagulable state with sickle cell disease related pulmonary hypertension. HAEMATOL-HEMATOL J 2008;93(5):e42-e44.     [ PubMed ]

van Beers EJ, van Eck-Smit BLF, Mac Gillavry MR, van Tuijn CFJ, van Esser JWJ, Brandjes DPM, Kappers-Klunne MC, Duits AJ, Biemond BJ, Schnog JJB. Large and medium-sized pulmonary artery obstruction does not play a role of primary importance in the etiology of sickle-cell disease-associated pulmonary hypertension. CHEST 2008;133(3):646-652.     [ PubMed ]

van Beers EJ, van Tuijn CFJ, Mac Gillavry MR, van der Giessen A, Schnog JJB, Biemond BJ. Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice. HAEMATOL-HEMATOL J 2008;93(5):757-760.     [ PubMed ]

van Dam IE, Kater AP , Hart W, van den Born BJH. Ernstige anemie door infectie met het Humaan parvovirus B19 bij een patiënt met een auto-immuun-hemolytische anemie en een B-cel-non-hodgkinlymfoom. NED TIJDSCHR GENEESKD 2008;152(3):153-157.     [ PubMed ]

van den Berg TK, van der Schoot CE. Innate immune 'self' recognition: a role for CD47-SIRP alpha interactions in hematopoietic stem cell transplantation. TRENDS IMMUNOL 2008;29(5):203-206.     [ PubMed ]

van der Laan A, Hirsch A, Nijveldt R, van der Vleuten PA, van der Giessen WJ, Doevendans PA, Waltenberger J, ten Berg JM, Aengevaeren WRM, Zwaginga JJ, Biemond BJ, van Rossum AC, Tijssen JGP, Zijlstra F, Piek JJ. Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results. NETH HEART J 2008;16(12):436-439.     [ PubMed ]

van der Lelie J. Voorzichtig met erytropoëtine bij patiëten met kanker. NED TIJDSCHR GENEESKD 2008;152(16):920-922.     [ PubMed ]

van der Schoot CE, Hahn S, Chitty LS. Non-invasive prenatal diagnosis and determination of fetal Rh status. SEMIN FETAL NEONATAL 2008;13(2):63-68.     [ PubMed ]

van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JAM, Vrisekoop N, Ackermans MAT, Ruiter AFC, Wittebol S, Eldering E, van Oers MHJ, Tesselaar K, Kersten MJ, Miedema F. In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. CANCER RES 2008;68(24):10137-10144.     [ PubMed ]

van Meerten T. Transfer and targeting of the human CD20 molecule. Utrecht: s.n.; 2008. (-pp.) (PhD thesis. Supervisor(s):  Hagenbeek A; co-supervisor(s):  Ebeling SB)

van Oers MHJ. Chronisch Lymfatische Leukemie (hoofdstuk 25).  In: Löwenberg B, Ossenkoppele GJ, editors. Handboek Hematologie. Utrecht: De Tijdstroom; 2008. p. 337-351.

Vellenga E, van Putten WLJ, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MHJ, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. BLOOD 2008;111(2):537-543.     [ PubMed ]

Vrisekoop N, den Braber I, de Boer AB, Ruiter AFC, Ackermans MT, van der Crabben SN, Schrijver EHR, Spierenburg G, Sauerwein HP, Hazenberg MD, de Boer RJ, Miedema F, Borghans JAM, Tesselaar K. Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. P NATL ACAD SCI USA 2008;105(16):6115-6120.     [ PubMed ]

Wever PC, Bos JC, van den Brekel MWM, de Jong D, Bovée LPMJ, Kersten MJ , Schellekens JFP, Kerst JM. Een waarschijnlijk geval van difterie. TIJDSCHR INFECTIEZIEKTEN 2008;3(6):230-235.  

Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. EXPERT OPIN BIOL TH 2008;8(8):1225-1240.     [ PubMed ]

Zeerleder S, Zwart B, te Velthuis H, Stephan F, Manoe R, Rensink I, Aarden LA. Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP). FASEB J 2008;22(12):4077-4084.     [ PubMed ]